Alignscience Pharma

Alignscience Pharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule precision medicines for oncology. The company leverages a proprietary structure-based drug design platform to target challenging drivers of cancer, with a primary focus on the RAS/MAPK signaling pathway. Its lead programs include highly selective inhibitors of KRAS mutations, such as G12D and G12V, as well as SOS1 inhibitors designed to overcome resistance in solid tumors. Headquartered in Suzhou, China, Alignscience aims to provide next-generation therapies for patients with genetically defined cancers who have limited treatment options.